What's new? Log in Free sign up

Table search / Eiger BioPharmaceuticals, Inc. / "Incentive"

2 results

Newest first Best match first

EIGRQ Eiger BioPharmaceuticals, Inc.

Annual report (amended)

		Option Awards																												Stock Awards
Name		Grant Date				Vesting Commencement Date				Number of Securities Underlying Unexercised Options (#) Exercisable				Number of Securities Underlying Unexercised Options (#) Unexercisable				Option Exercise Price ($)				Option Expiration Date				Number of Shares or Units of Stock That Have Not Vested (#)				Market Value of Shares or Units of Stock That Have Not Vested ($)(1)				Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)				Equity Incentive Plan Awards: Market or payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)
David Apelian			9/28/2017				6/14/2017	(4)			833				—				322.50				9/27/2027								1/5/2018				1/3/2018	(3)			834				—				411.00				1/4/2028								1/5/2018				1/3/2018	(3)			4,165				—				411.00				1/4/2028								3/14/2018				3/14/2018	(2)			925				—				285.00				3/13/2028								3/14/2018				3/14/2018	(2)			308				—				285.00				3/13/2028								3/21/2019				3/21/2019	(2)			3,371				—				429.30				3/20/2029								3/21/2019				3/21/2019	(2)			312				—				429.30				3/20/2029								3/12/2020				3/12/2020	(7)			333				—				168.00				3/11/2030								3/12/2021				3/12/2021	(7)			333				—				299.70				3/11/2031								3/11/2022				3/11/2022	(7)			400				—				153.00				3/10/2032								1/31/2023				12/14/2022	(9)			1,870				—				49.50				06/14/2033								1/31/2023				12/14/2022	(10)			150				—				49.50				01/31/2033								1/31/2023				12/14/2022	(10)			3,646				—				49.50				01/31/2033								7/3/2023				07/03/2023	(2)			2,600				5,036				21.87				07/03/2033								7/3/2023				07/03/2023	(2)			—				17,363				21.87				07/03/2033						Eldon Mayer			1/5/2018				1/5/2018	(4)			416				—				411.00				1/4/2028								3/14/2018				3/14/2018	(7)			166				—				285.00				3/13/2028								3/21/2019				3/21/2019	(7)			166				—				429.30				3/20/2029								1/31/2020				1/6/2020	(3)			3,072				—				370.80				1/30/2030								1/31/2020				1/6/2020	(3)			608				94				370.80				1/30/2030								3/12/2021				3/12/2021	(2)			1,628				393				299.70				3/11/2031								3/12/2021				3/12/2021	(2)			—				353				299.70				3/11/2031								3/12/2021				3/12/2021	(5)			—				—				—				—				131				822.29						7/29/2021				7/29/2021	(4)			469				114				244.50				7/28/2031								7/29/2021				7/29/2021	(6)			—				—				—				—						700				4,714.50
		3/11/2022				3/11/2022	(5)			—				—				—				—				355				2,390.93						3/11/2022				3/11/2022	(2)			—				567				153.00				3/10/2032								3/11/2022				3/11/2022	(2)			1,426				1,273				153.00				3/10/2032								1/26/2023				01/25/2023	(11)			—				953				41.10				01/26/2033								1/26/2023				01/25/2023	(11)			—				96				41.10				01/26/2033								3/1/2023				03/01/2023	(2)			259				1,022				51.30				03/01/2033								3/1/2023				03/01/2023	(2)			351				1,633				51.30				03/01/2033						James A. Vollins			4/28/2023				04/10/2023	(2)			666				3,334				30.90				04/28/2033

EIGRQ Eiger BioPharmaceuticals, Inc.

Annual report (amended)

The following 2023 Summary Compensation Table and narrative disclosure sets forth information regarding the compensation of our named executive officers for the years ended December 31, 2023 and, to the extent required by SEC disclosure rules, December 31, 2022.

Name and Principal Position		Year				Salary ($)				Bonus ($)(1)				Stock Awards ($)(2)				Option Awards ($)(3)				Non-Equity Incentive Plan Compensation ($)(4)				All Other Compensation ($)(5)				Total ($)
David Apelian			2023				625,699				78,000				—				631,866				139,866				3,461				1,478,892
Chief Executive Officer			2022				30,875				—				—				—				—				173,511				204,386
Eldon Mayer			2023				438,021				35,000				—				160,282				—				4,902				638,205
Former Chief Commercial Officer			2022				410,000					81,600				312,444				172,200				4,763				981,007
James A. Vollins			2023				309,896				34,000				—				94,368				105,307				4,553				548,124
General Counsel, Corp. Sec. and Chief Compliance Officer

Prev
1
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.